.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Teva
Federal Trade Commission
Dow
Cerilliant
Chinese Patent Office
Moodys
Healthtrust
Cipla

Generated: July 28, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,211,600 protect, and when does it expire?


Patent ► Subscribe protects SUTENT and is included in one NDA. There has been one Paragraph IV challenge on Sutent.

This patent has thirteen patent family members in thirteen countries.

Summary for Patent: ► Subscribe

Title:Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Abstract:The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
Inventor(s): Lipson; Ken (San Mateo, CA), McMahon; Gerald (Kenwood, CA)
Assignee: Sugen Inc. (South San Francisco, CA)
Application Number:11/205,474
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-001Jan 26, 2006RXYesNo► Subscribe► Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-002Jan 26, 2006RXYesNo► Subscribe► Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-004Mar 31, 2009RXYesNo► Subscribe► Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-003Jan 26, 2006RXYesYes► Subscribe► Subscribe TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria331514► Subscribe
Australia3436301► Subscribe
Australia784266► Subscribe
Canada2395461► Subscribe
Germany60029138► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
McKinsey
Johnson and Johnson
QuintilesIMS
Teva
Colorcon
Healthtrust
Fish and Richardson
Argus Health
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot